Coronavirus Disease 2019 (COVID-19) MedDRA version: 23.1 Level: PT Classification code 10084460 Term: COVID-19 treatment System Organ Class: 10042613 - Surgical and medical procedures
Conditions
Sponsors
Pfizer Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Participants =18 years of age (or the minimum country-specific age of consent if >18) at the time of the Screening Visit. - WOCBP may be enrolled. - All fertile participants must agree to use a highly effective method of contraception. Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants. 2.Confirmed SARS-CoV-2 infection as determined by RT-PCR in any specimen collected within 5 days prior to randomization. Note: RT-PCR is the preferred method; however, with evolving approaches to confirmation of SARS-CoV-2 infection, other molecular or antigen tests that detect viral RNA or protein are allowed. The test result must be available to confirm eligibility. Participants may be enrolled based on positive results of a rapid SARS-CoV-2 antigen test performed at screening. 3.Initial onset of signs/symptoms attributable to COVID-19 within 5 days prior to the day of randomization and at least 1 of the specified signs/symptoms attributable to COVID-19 present on the day of randomization (see Appendix 9 for criteria). 4.Has at least 1 characteristic or underlying medical condition associated with an increased risk of developing severe illness from COVID-19 including: - =60 years of age; - BMI >25; - Current smoker (cigarette smoking within the past 30 days) and history of at least 100 lifetime cigarettes; - Immunosuppressive disease (eg, bone marrow or organ transplantation or primary immune deficiencies) OR prolonged use of immune-weakening medications: o Has received corticosteroids equivalent to prednisone =20 mg daily for at least 14 consecutive days within 30 days prior to study entry. o Has received treatment with biologics (eg, infliximab, ustekinumab), immunomodulators (eg, methotrexate, 6MP, azathioprine) or cancer chemotherapy within 90 days prior to study entry. o HIV infection with CD4 cell count =65 years) yes F.1.3.1 Number of subjects for this age range 300
Exclusion criteria
Exclusion criteria: 1. History of hospitalization for the medical treatment of COVID-19. 2. Current need for hospitalization or anticipated need for hospitalization within 48 hours after randomization in the clinical opinion of the site investigator (see Section 8.1.2.) 3. Prior to current disease episode, any confirmed SARS-CoV-2 infection, as determined by a molecular test (antigen or nucleic acid) from any specimen collection. 4. Known medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic or active hepatitis B or C infection, primary biliary cirrhosis, Child-Pugh Class B or C, or acute liver failure. 5. Receiving dialysis or have known moderate to severe renal impairment [ie, eGFR <45 mL/min/1.73 m2 within 6 months of the screening visit, using the serum creatinine-based CKD-EPI formula] 6. Known HIV infection with a viral load greater than 400 copies/mL or taking prohibited medications for HIV treatment from known medical history within past 6 months of the screening visit) (Appendix 8). 7. Suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study intervention. 8. Any comorbidity requiring hospitalization and/or surgery within 7 days prior to study entry, or that is considered life threatening within 30 days prior to study entry, as determined by the investigator. 9. History of hypersensitivity or other contraindication to any of the components of the study intervention, as determined by the investigator. 10. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study. 11. Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance and for which elevated plasma concentrations may be associated with serious and/or life-threatening events during treatment and for 4 days after the last dose of PF-07321332/ritonavir (See Appendix 8). 12. Concomitant use of any medications or substances that are strong inducers of CYP3A4 are prohibited within 28 days prior to first dose of PF-07321332/ritonavir and during study treatment (see Appendix 8). 13. Has received or is expected to receive convalescent COVID-19 plasma. 14. Has received or is expected to receive any dose of a SARS-CoV-2 vaccine before the Day 34 visit. 15. Is unwilling to abstain from participating in another interventional clinical study with an investigational compound or device, including those for COVID-19 therapeutics, through the long-term follow-up visit. 16. Previous administration with any investigational drug or vaccine within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer). 17. Known prior participation in this trial or other trial involving PF-07321332. 18. Known history of any of the following abnormalities in clinical laboratory tests (within past 6 months of the screening visit): - AST or ALT level =2.5 X ULN; - Total bilirubin =2 X ULN (=3 X ULN for Gilbert’s syndrome); - Absolute neutrophil count <1000/mm3. - GFR <45 mL/min/1.73 m2 within 6 months of the screening visit, using the serum creatinine-based CKD-EPI formula30 Note: If the investigator suspects the participant may have any
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare the efficacy of PF-07321332/ritonavir to placebo for the treatment of COVID-19 in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progression to severe disease.;Secondary Objective: -To describe the safety and tolerability of PF-07321332/ritonavir relative to placebo in the treatment of nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progression to severe disease. - To compare the efficacy of PF 07321332/ritonavir to placebo for the treatment of COVID-19 in nonhospitalized symptomatic adult participants with COVID 19 who are at increased risk of progression to severe disease. -To compare PF-07321332/ritonavir to placebo for all-cause mortality in nonhospitalized symptomatic adult participants with COVID-19 who are at increased risk of progression to severe disease. -To determine the PK of PF-07321332 in nonhospitalized symptomatic adult participants with COVID 19 who are at increased risk of progression to severe disease. *details of remaining objectives in Protocol;Primary end point(s): Proportion of participants with COVID-19 related hospitalization or death from any cause through Day 28. ;Timepoint(s) of evaluation of this end point: - through day 28 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): - Incidence of TEAEs. - Incidence of SAEs and AEs leading to discontinuations. - Proportion of participants with COVID-19-related hospitalization or death from any cause through Day 28 - Time (days) to sustained alleviation of all targeted signs/symptoms through Day 28. - Proportion of participants with severe signs/symptoms attributed to COVID-19 through Day 28. - Time (days) to sustained resolution of all targeted signs/symptoms through Day 28. - Duration of each targeted COVID 19 sign/symptom. - Progression to a worsening status in 1 or more self reported COVID 19 associated symptoms through Day 28. - Proportion of participants with a resting peripheral oxygen saturation =95% at Days 1 and 5. - Proportion of participants with death (all cause) through Week 24. - PF 07321332 PK in plasma and whole blood (if feasible). - Viral titers measured via RT-PCR in nasal swabs over time. - Number of COVID-19 related medical visits through Day 28. - Number of days in hospital and ICU stay in participants with COVID-19 related hospitalization. ;Timepoint(s) of evaluation of this end point: throughout the study | — |
Countries
Argentina, Brazil, Bulgaria, China, Colombia, Czechia, Czech Republic, Hungary, India, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, Peru, Poland, Puerto Rico, Russian Federation, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
Contacts
Public ContactClinical Trials.gov Call Centre
Pfizer Inc.
Outcome results
None listed